CAR T cells targeting CD19 or other B cell markers such as CD20 have achieved remarkable responses in patients with B cell malignancies including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and lymphoma [26, 46–48]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.